| Diabetes Mellitus
Fiasp vs Toujeo
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Fiasp vs Toujeo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsToujeo has a higher rate of injection site reactions vs Fiasp based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Toujeo but not Fiasp, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fiasp
Toujeo
At A Glance
SC injection
With meals
Rapid-acting insulin analog
SC injection
Once daily
Long-acting insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus - SC injection Inject at start of meal or within 20 minutes after starting a meal into abdomen, upper arm, or thigh; generally use with intermediate- or long-acting insulin; individualize dose based on metabolic needs and blood glucose monitoring.
Diabetes Mellitus - Insulin pump (CSII) Administer by continuous SC infusion using an insulin pump; change FIASP reservoir at least every 6 days or PumpCart at least every 4 days; do not mix with other insulins in the pump.
Diabetes Mellitus - IV infusion Administer only under medical supervision; dilute to 0.5-1 unit/mL in polypropylene infusion bags with 0.9% sodium chloride or 5% dextrose; stable at room temperature for 24 hours.
Diabetes Mellitus, Type 1 (insulin-naive) Approximately one-third to one-half of total daily insulin dose SC once daily; remainder given as short-acting insulin divided between daily meals.
Diabetes Mellitus, Type 2 (insulin-naive) 0.2 units/kg SC once daily.
Switching from once-daily long/intermediate-acting insulin Start at same unit dose as prior once-daily long-acting insulin SC once daily; monitor glucose closely during initial weeks.
Switching from twice-daily long/intermediate-acting insulin Start at 80% of total daily NPH or insulin detemir twice-daily dosage SC once daily; monitor glucose frequently.
Contraindications
- Episodes of hypoglycemia
- Known hypersensitivity to insulin aspart or any excipient in FIASP
- Active hypoglycemia episode
- Hypersensitivity to insulin glargine or any excipient in Toujeo
Adverse Reactions
Most common (>=5%) Nasopharyngitis, upper respiratory tract infection, nausea, diarrhea, back pain (adults with T1D); urinary tract infection (adults with T2D); viral upper respiratory tract infection, upper respiratory tract infection, influenza, headache, pyrexia, vomiting (pediatric T1D)
Serious Hypoglycemia, hypokalemia, severe hypersensitivity reactions including anaphylaxis, angioedema, bronchospasm, hypotension, and shock; lipodystrophy; injection or infusion site reactions; peripheral edema; weight gain
Postmarketing Localized cutaneous amyloidosis at injection site; hyperglycemia with repeated injections into amyloidosis areas; hypoglycemia with sudden change to unaffected injection site
Most common (>=5%) nasopharyngitis, upper respiratory tract infection, hypoglycemia
Serious severe hypoglycemia, anaphylaxis, peripheral edema, lipodystrophy, hypokalemia
Postmarketing localized cutaneous amyloidosis at injection site, hyperglycemia or hypoglycemia associated with injections into or away from amyloidosis areas
Pharmacology
Rapid-acting insulin analog; binds to insulin receptors to lower blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and inhibiting hepatic glucose output, while also inhibiting lipolysis and proteolysis and enhancing protein synthesis.
Long-acting insulin analog; regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat, inhibiting hepatic glucose production, inhibiting lipolysis and proteolysis, and enhancing protein synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fiasp
- Covered on 5 commercial plans
- PA (8/12) · Step Therapy (9/12) · Qty limit (8/12)
Toujeo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Fiasp
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Toujeo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Fiasp
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Toujeo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Fiasp.
No savings programs available for Toujeo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.